Freenome Holdings, Inc., a pioneering force in the biotechnology sector, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in the development of advanced multi-omics technology for early cancer detection. Freenome's innovative approach combines artificial intelligence with blood-based biomarker analysis, offering unique insights that enhance diagnostic accuracy. With a focus on colorectal cancer screening, Freenome's flagship product stands out for its ability to detect cancer at its earliest stages, significantly improving patient outcomes. The company has achieved notable milestones, including partnerships with leading healthcare institutions and recognition for its contributions to cancer diagnostics. As a key player in the oncology landscape, Freenome continues to drive advancements that redefine cancer detection and management.
How does Freenome Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Freenome Holdings, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Freenome Holdings, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that Freenome may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for Freenome to establish clear climate commitments and reduction initiatives to align with global standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Freenome Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
